Recent developments once again demonstrate how differently operational progress, corporate news, market sentiment, and valuation can turn out, even within structurally attractive investment cases.
Revolution Medicines reaches the threshold for commercial marketing of its own drug for the first time with the FDA approval of Daraxonrasib.
PayPal, on the other hand, loses a significant driver of its recent price recovery with the withdrawal of Stripe and Advent.
Palantir once again demonstrates the extraordinary dynamics surrounding artificial intelligence, data analytics, and defense technology. At the same time, the question of technological sovereignty is moving more into focus, particularly in Europe.
The three MUMAK HotSpot Stories this week thus differ significantly: Revolution Medicines faces the transition from clinical development to commercial revenue, PayPal continues to work on its operational turnaround, and Palantir must combine exceptional growth with an already very ambitious valuation.
Revolution Medicines: FDA approval changes the investment case
For Revolution Medicines, this week brought the most important milestone in the company’s history to date.
On August 26, 2026, the US FDA approved Daraxonrasib under the brand name RASONQUE for the treatment of certain patients with metastatic pancreatic cancer.
This gives Revolution Medicines its first proprietary approved drug.
The decision is based on the exceptionally strong results of the Phase 3 RASolute 302 study.
Median overall survival increased from 6.7 months under standard chemotherapy to 13.2 months under Daraxonrasib.
At the same time, the risk of death was reduced by approximately 60% compared to chemotherapy.
Daraxonrasib also showed statistically significant advantages in progression-free survival and objective response rate.
This difference is of particular importance in metastatic pancreatic cancer, as the disease remains one of the most therapeutically challenging tumor types.
The speed of the regulatory process was also remarkable.
The FDA granted approval approximately 6.5 months ahead of the original target date.
As a result, one of the most important regulatory catalysts for the investment case has now become a reality.
The next step is commercialization
With this approval, the investment story for Revolution Medicines changes.
Previously, the company was primarily valued based on its clinical pipeline and the future potential of its RAS(ON) platform.
With RASONQUE, the phase begins in which the technology can generate actual product revenue for the first time.
At the same time, the comparatively controlled reaction of the share price was interesting.
Following the approval, the price rose by approximately 1.9% on Wednesday and another 2.4% on Thursday.
This suggests that the market had already priced in a significant portion of the positive regulatory development in advance.
The focus is therefore now shifting increasingly toward commercial execution.
The decisive factor will be how quickly RASONQUE is adopted by doctors and patients and what revenues Revolution Medicines can achieve in the coming quarters.
The larger lever remains the RAS platform
However, the investment story continues to extend well beyond Daraxonrasib and pancreatic cancer.
Revolution Medicines is developing further mutation-specific agents alongside the broad-acting RAS(ON) inhibitor Daraxonrasib.
These include, in particular, Zoldonrasib and Elironrasib, as well as additional programs within the RAS pipeline.
The long-term lever therefore lies in whether the clinical success of Daraxonrasib can be transferred to other RAS-driven tumor types.
Possible applications in larger indications such as lung and colorectal cancer remain particularly relevant.
Assessment by the MUMAK® UMBRELLA Strategy
Revolution Medicines reaches a decisive new level of maturity within its investment case with the approval of RASONQUE.
Regulatory risk for the first product has been substantially reduced.
The central question now shifts from approval to commercial scaling.
At the same time, the high valuation remains a key factor.
The market is already pricing in significant future revenues as well as additional successes within the RAS pipeline.
The decisive factor will therefore be whether Revolution Medicines can actually develop a broader and commercially significant RAS oncology platform from one successful drug.
PayPal: Takeover speculation ends abruptly
For PayPal, by contrast, the week took a significantly more negative turn.
According to recent reports, a consortium consisting of the payment service provider Stripe and the financial investor Advent International is no longer pursuing a possible acquisition of the company.
Previously, the group had bid approximately $60.50 per share, or about $53 billion, for PayPal.
Speculation about a possible transaction had contributed significantly to the recent price recovery.
With the withdrawal of the potential buyers, a key short-term price driver now disappears.
The market reaction was correspondingly sharp.
PayPal shares lost more than 15% at times in US pre-market trading on Friday.
Previously, the share price had improved by more than 40% at times during the current quarter – also supported by the takeover speculation.
Focus returns to the operating business
Fundamentally, the failed takeover does not change PayPal’s actual business for now.
However, it does change the perception of the investment case.
Since a significant portion of the recent price development was driven by the possibility of a company sale, the operational transformation, growth in the core business, and future profitability must now once again be convincing.
PayPal still possesses a global payment infrastructure and approximately 440 million active accounts.
At the same time, competitive pressure remains significant.
In addition to traditional payment service providers, PayPal increasingly competes with platforms such as Apple Pay, Google Pay and numerous other fintech solutions.
The central question therefore remains whether PayPal can more effectively monetize its large user base again while simultaneously developing new growth drivers.
Assessment by the MUMAK® UMBRELLA Strategy
For PayPal, the loss of takeover speculation short-term particularly increases the importance of technical risk management.
The fundamental turnaround story is not over.
However, the market must now evaluate the company more strongly based on its own operational development.
The development of transaction volumes, future profitability, and progress in strategic repositioning remain decisive.
At the same time, the recent price decline shows how strongly the previous revaluation was at least partially dependent on an external catalyst.
Palantir: Momentum returns
For Palantir, by contrast, the extraordinary strength of the stock was again evident during the week.
After price losses at the beginning of the week, momentum turned significantly upward starting Wednesday.
On Wednesday, the stock rose by approximately 2.8%.
A further increase of 4.75% to $185.93 followed on Thursday.
This allowed Palantir to largely recover the initial weekly losses within a short period.
Support again came from the positive market sentiment surrounding artificial intelligence and technology stocks.
A new company-specific major order was not the focus.
Rather, the price movement shows how strongly the market continues to categorize Palantir as one of the most important listed beneficiaries of the increasing commercial and governmental use of artificial intelligence.
AI, Defense, and Government Infrastructure
Palantir’s unique positioning now goes well beyond traditional enterprise software.
The company combines data analytics, artificial intelligence, defense, and government infrastructure within a common software platform.
It is precisely this combination that distinguishes Palantir from many other technology companies.
Alongside the rapidly growing commercial business, government, security, and defense contracts continue to play a central role.
The company thus benefits simultaneously from two structural developments:
the increasing use of artificial intelligence in companies and the digitalization of modern defense and security structures.
Europe simultaneously becomes a strategic risk
However, a development from Europe was also interesting this week.
The French software group ChapsVision is increasingly positioning itself as a European alternative to Palantir and has received a contract to replace Palantir technology within a French intelligence service.
At the same time, the company is attempting to gain a stronger foothold with German authorities.
This makes a long-term risk more visible: technological sovereignty.
Particularly with highly sensitive government, defense, and intelligence data, European states could attempt to reduce their dependence on US technology companies.
This changes little in the short term regarding Palantir’s exceptionally strong market position.
In the long term, however, the question of national and European data and technology sovereignty could determine how large the actual addressable market for Palantir with European authorities will be.
Assessment by the MUMAK® UMBRELLA Strategy
Palantir remains one of the most operationally dynamic companies within the current AI investment cycle.
Strong growth, technological positioning, and the increasing importance of artificial intelligence in companies and government institutions continue to support the long-term investment case.
At the same time, exceptionally high future expectations are already included in the valuation.
The decisive factor therefore remains whether Palantir can maintain its high growth momentum over several years.
Additionally, geopolitical and regulatory factors are gaining importance.
Technological sovereignty, data protection, and possible political restrictions could play a larger role in the long term, particularly with European government contracts.
Revolution Medicines, PayPal, and Palantir: Different companies in the SpotLight
Key Takeaway
The three companies currently represent very different opportunities and risks within the MUMAK® UMBRELLA Strategy.
Revolution Medicines reaches a decisive milestone with the FDA approval of RASONQUE. An investment case previously dominated by clinical factors is becoming a commercial investment case for the first time. The decisive factor now will be how quickly clinical success can be translated into relevant revenue. The larger long-term lever remains the entire RAS platform.
PayPal, by contrast, loses a significant short-term price driver with the withdrawal of Stripe and Advent. This brings operational development back into focus. The decisive factor will be whether the company can drive its turnaround forward on its own and sustainably improve growth and profitability.
Palantir simultaneously confirms its exceptional position within the AI investment cycle. Strong growth, artificial intelligence, and increasing defense applications remain key structural drivers. At the same time, the high valuation and increasing discussions about technological sovereignty continue to require special attention.
The current assessment can therefore be summarized simply:
Revolution Medicines must now translate clinical success into revenue – PayPal must prove its turnaround without takeover speculation – Palantir must deliver exceptional growth to meet exceptional expectations.
From the perspective of the MUMAK® UMBRELLA Strategy, corporate developments, market sentiment, valuation, and technical signals remain decisive for how the individual positions within the strategy are managed.
In the video: Are Palantir and SpaceX the new defense stocks?
Are SpaceX and Palantir the new defense stocks – or is there still no way around classic defense names like Rheinmetall, Thales and TKMS?
Together with the SdK Schutzgemeinschaft der Kapitalanleger e.V., we take a look at five exciting defense and AI companies and why they currently play a role within the MUMAK® UMBRELLA Strategy.
The focus is on Rheinmetall with European defense and a high order backlog, TKMS with submarines and naval systems, and Thales with radar, communications, cybersecurity, and aerospace.
At the same time, new technology companies are increasingly changing the definition of modern defense.
This increasingly raises the question of whether defense in the future will no longer be defined exclusively by classic armament groups, but also by software, artificial intelligence, data, and space infrastructure.
